Metformin Colonis

Metformin Hydrochloride, the active ingredient in Metformin Colonis, is a Biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving insulin sensitivity and reducing hepatic glucose production.

GNH USA supplies Metformin Colonis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Metformin Colonis is indicated for the management of type 2 diabetes mellitus, the primary disease state targeted by this biguanide.

- Type 2 diabetes mellitus (fasting hyperglycemia): lowers fasting plasma glucose and HbA1c. - Type 2 diabetes mellitus (postprandial hyperglycemia): reduces post‑meal glucose excursions. - Type 2 diabetes mellitus (combination therapy): enhances overall glycemic control when added to other antidiabetic agents.

Metformin Colonis may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycemia: uncommon when used alone, may occur with other agents. - Hepatic dysfunction: elevated liver enzymes. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Anemia: reduction in red blood cell count.

When prescribing Metformin Colonis, clinicians should consider several safety measures.

- Renal function assessment: avoid use in patients with eGFR <30 mL/min/1.73 m². - Hepatic impairment: use with caution in moderate liver disease. - Cardiovascular status: monitor for heart failure as risk of lactic acidosis increases. - Concomitant contrast imaging: discontinue before iodinated contrast procedures. - Vitamin B12 monitoring: long‑term therapy may reduce B12 levels; check periodically. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Metformin Colonis can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Nucleoside reverse transcriptase inhibitors (e.g., didanosine): raise risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides, loop): may impair renal clearance of metformin. - ACE inhibitors/ARBs: can affect renal function, requiring dose adjustment. - Beta‑blockers: may mask hypoglycemia symptoms when combined with other agents. - Oral corticosteroids: may increase blood glucose, necessitating dose titration.